CA2574032C - Compounds and methods for the treatment of cancer - Google Patents

Compounds and methods for the treatment of cancer Download PDF

Info

Publication number
CA2574032C
CA2574032C CA2574032A CA2574032A CA2574032C CA 2574032 C CA2574032 C CA 2574032C CA 2574032 A CA2574032 A CA 2574032A CA 2574032 A CA2574032 A CA 2574032A CA 2574032 C CA2574032 C CA 2574032C
Authority
CA
Canada
Prior art keywords
cancer
compound
pharmaceutical composition
cells
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2574032A
Other languages
English (en)
French (fr)
Other versions
CA2574032A1 (en
Inventor
Ralph A. Zingaro
Hatice Duzkale
Emil J. Freireich
Hagop Kantarjian
Merida Sotelo-Lerma
Srdan Verstovsek
Mingzhang Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
The University of Texas System
Original Assignee
Texas A&M University System
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System, The University of Texas System filed Critical Texas A&M University System
Priority to CA2777473A priority Critical patent/CA2777473C/en
Publication of CA2574032A1 publication Critical patent/CA2574032A1/en
Application granted granted Critical
Publication of CA2574032C publication Critical patent/CA2574032C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C07F9/82—Arsenic compounds containing one or more pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2574032A 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer Expired - Fee Related CA2574032C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2777473A CA2777473C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58859604P 2004-07-16 2004-07-16
US60/588,596 2004-07-16
PCT/US2005/025192 WO2006020048A2 (en) 2004-07-16 2005-07-15 Compounds and methods for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2777473A Division CA2777473C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2574032A1 CA2574032A1 (en) 2006-02-23
CA2574032C true CA2574032C (en) 2015-02-24

Family

ID=35414967

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2574032A Expired - Fee Related CA2574032C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer
CA2777473A Expired - Fee Related CA2777473C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2777473A Expired - Fee Related CA2777473C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Country Status (11)

Country Link
US (2) US7405314B2 (enExample)
EP (1) EP1771459A2 (enExample)
JP (3) JP5618461B2 (enExample)
KR (5) KR101252866B1 (enExample)
CN (3) CN105777811A (enExample)
AU (1) AU2005274926B2 (enExample)
CA (2) CA2574032C (enExample)
HK (1) HK1204476A1 (enExample)
IL (2) IL180729A (enExample)
TW (3) TWI411431B (enExample)
WO (1) WO2006020048A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4571408B2 (ja) 2002-01-07 2010-10-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
TWI411431B (zh) 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
CN101395166B (zh) * 2006-01-13 2014-07-09 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
RU2318519C2 (ru) * 2006-03-06 2008-03-10 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ химиотерапии острого лейкоза
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CN101903029B (zh) * 2007-11-02 2012-09-26 Zio医药肿瘤学公司 使用有机砷化物的联合治疗
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
CA2734650A1 (en) * 2008-08-20 2010-02-25 Ziopharm Oncology, Inc. Organoarsenic compounds and methods for the treatment of cancer
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
ES2970433T3 (es) 2009-08-13 2024-05-28 Acufocus Inc Método de fabricación de implantes intraoculares con máscara y lentes
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
JP6046160B2 (ja) 2011-12-02 2016-12-14 アキュフォーカス・インコーポレーテッド 選択的分光透過性を有する眼科マスク
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
GB201418491D0 (en) * 2014-10-17 2014-12-03 Monfort University De Compounds
EP3220859B8 (en) 2014-11-19 2020-06-10 AcuFocus, Inc. Fracturable mask for treating presbyopia
US10687935B2 (en) 2015-10-05 2020-06-23 Acufocus, Inc. Methods of molding intraocular lenses
CA3005891C (en) 2015-11-24 2023-12-12 Acufocus, Inc. Toric small aperture intraocular lens with extended depth of focus
CN105330701B (zh) * 2015-11-27 2017-05-31 昆明医科大学 一种含砷化合物及其制备方法和应用
EP3790508B1 (en) 2018-05-09 2026-04-29 AcuFocus, Inc. Intraocular implant with optic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391206B1 (en) 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
JP4571408B2 (ja) * 2002-01-07 2010-10-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
TWI411431B (zh) * 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物

Also Published As

Publication number Publication date
JP2008506710A (ja) 2008-03-06
KR20130095857A (ko) 2013-08-28
CA2574032A1 (en) 2006-02-23
HK1204476A1 (en) 2015-11-20
JP2014122233A (ja) 2014-07-03
IL180729A (en) 2012-03-29
JP5745660B2 (ja) 2015-07-08
IL180729A0 (en) 2007-06-03
CA2777473A1 (en) 2006-02-23
CA2777473C (en) 2013-08-27
CN105777811A (zh) 2016-07-20
KR20140136525A (ko) 2014-11-28
TW200616615A (en) 2006-06-01
KR20130001323A (ko) 2013-01-03
KR20070046120A (ko) 2007-05-02
CN104163833A (zh) 2014-11-26
EP1771459A2 (en) 2007-04-11
KR101252866B1 (ko) 2013-04-10
CN101076533B (zh) 2013-11-06
WO2006020048A3 (en) 2006-08-24
US7405314B2 (en) 2008-07-29
WO2006020048A2 (en) 2006-02-23
TWI411431B (zh) 2013-10-11
KR20140013110A (ko) 2014-02-04
US20060128682A1 (en) 2006-06-15
WO2006020048B1 (en) 2006-10-19
JP2012051919A (ja) 2012-03-15
JP5618461B2 (ja) 2014-11-05
IL215896A0 (en) 2011-12-29
AU2005274926A1 (en) 2006-02-23
TW201350113A (zh) 2013-12-16
CN101076533A (zh) 2007-11-21
AU2005274926B2 (en) 2011-04-28
US20080090793A1 (en) 2008-04-17
TW201440760A (zh) 2014-11-01

Similar Documents

Publication Publication Date Title
US20080090793A1 (en) Compounds and methods for the treatment of cancer
US11324714B2 (en) Organoarsenic compounds and methods for the treatment of cancer
EP1474128B1 (en) S-dimethylarsino-thiosuccinic acid, s-dimethylarsino-2-thiobenzoic acid, s-(dimethylarsino)glutathione as treatments for cancer
AU2011204901B2 (en) Compounds and methods for treatment of cancer
CA2636793A1 (en) Compounds and methods for the treatment of cancer
AU2007249110C1 (en) S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer
HK1166959A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
HK1171952A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160715